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Abstract
Background/Objective: Parkinson’s disease (PD) and the atypical parkinsonian syndromes multiple system atrophy (MSA),
progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) are movement disorders associated with
degeneration of the central nervous system. Degeneration of the retina has not been systematically compared in these
diseases.
Methods: This cross-sectional study used spectral-domain optical coherence tomography with manual segmentation to
measure the peripapillar nerve fiber layer, the macular thickness, and the thickness of all retinal layers in foveal scans of 40
patients with PD, 19 with MSA, 10 with CBS, 15 with PSP, and 35 age- and sex-matched controls.
Results: The mean paramacular thickness and volume were reduced in PSP while the mean RNFL did not differ significantly
between groups. In PSP patients, the complex of retinal ganglion cell- and inner plexiform layer and the outer nuclear layer
was reduced. In PD, the inner nuclear layer was thicker than in controls, MSA and PSP. Using the ratio between the outer
nuclear layer and the outer plexiform layer with a cut-off at 3.1 and the additional constraint that the inner nuclear layer be
under 46 mm, we were able to differentiate PSP from PD in our patient sample with a sensitivity of 96% and a specificity of
70%.
Conclusion: Different parkinsonian syndromes are associated with distinct changes in retinal morphology. These findings
may serve to facilitate the differential diagnosis of parkinsonian syndromes and give insight into the degenerative processes
of patients with atypical parkinsonian syndromes.
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Introduction
Parkinson’s disease (PD) and the atypical parkinsonian syn-
dromes multiple system atrophy (MSA), progressive supranuclear
palsy (PSP) and corticobasal syndrome (CBS) are movement
disorders associated with degeneration of the central nervous
system. Several volumetric MRI studies have reported differences
between the different parkinsonian syndromes [1,2,3,4]. In all four
diseases, abnormalities of the visual system have been described. In
PD, prolonged latencies of visually evoked potentials (VEP) [5]
and deficits in contrast sensitivity and color vision [6,7] have been
reported. Also, the function of retinal ganglion cells seems to be
altered as shown by pattern electroretinograms (ERG) [8,9,10,11].
In a patient with MSA, optic disc pallor and negative ERGs were
observed [12]. Visual event related potentials using a visual
oddball paradigm were reported to be abnormal in all four
diseases [13]. The often-observed blurry vision of PSP patients is
usually attributed to the pronounced impairment of ocular
movements and diplopia [14], but might also be associated with
retinal changes. PSP and CBS have been reported to be associated
with visuospatial deficits [15]. A post-mortem study using high
performance liquid chromatography suggested a reduction in the
dopamine content of retinas of PD patients [16].
Optical coherence tomography (OCT) is a non-invasive optical
interferometric method generating cross-sectional images of the
retina in vivo, which has revolutionized retinal imaging since its
introduction in the 1990s [17]. Since then OCT has been applied
to a variety of disorders of the central nervous system (CNS) with
an emphasis on chronic inflammatory CNS diseases like multiple
sclerosis (MS) [18,19,20,21,22,23]. Several small studies examined
the retinal morphology in PD using OCT with different results:
Two studies found a significant reduction of the peripapillar retinal
nerve fiber layer (RNFL) thickness in 10 and 16 patients with PD
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Others reported a reduction of the mean total peripapillar RNFL
thickness and macular volume in 17 PD patients and an inverse
correlation of macular thickness with part III of the unified
Parkinson’s disease rating scale (UPDRS-III) [26]. Another study
with 24 PD patients reported thinning of the parafoveal inner
retinal layers consisting of the RNFL, the retinal ganglion cell layer
(RGC), and the inner plexiform layer (IPL) using Fourier domain
OCT [27]. However, others could not reproduce these changes
[28,29]. Recently, a small OCT study with 10 patients reported a
reduction of the RNFL thickness in MSA [30]. In our study, we
used last-generation spectral-domain OCT to analyze the largest
collective of PD patients to date and included patients suffering
from atypical parkinsonian syndromes including MSA, PSP, and
CBS.
We present a complete dataset of the retinal parameters
routinely accessible to modern OCT technology and additionally
manually measured the thickness of the different retinal layers in
cross-sectional foveal scans, which demonstrated profound differ-
ences between these diseases. The strength of this study is that we
analyzed all parafoveal retinal layers and systematically compared
typical and atypical parkinsonian syndromes.
Materials and Methods
Ethics
Patients examined in this study were recruited from a large
longitudinal study on patients with movement disorders, approved
by the local ethics committee, the ‘‘Ethikkommission der
Medizinischen Fakulta ¨t der Heinrich-Heine-Universita ¨t Du ¨ssel-
dorf, Ethikkommission@med.uni-duesseldorf.de’’. Within this
study, we performed morphometric MRI scans, neuropsychologic
tests and at one time point optical coherence tomography (OCT)
measurements. OCT is a fast, non-invasive and not painful
method and is included in the routine diagnostic program for
patients with movement disorders at our center. Written informed
consent was given by all subjects for data acquisition, MRI
morphometry, and clinical and neuropsychologic examinations.
Before the actual OCT examination, the procedure and the
reason for this examination in particular were explained to the
patients in full detail and additional informed consent was
obtained verbally. This procedure was approved by the local
ethics committee in an amendment to the initial ethics votum.
Patients
We examined 40 patients with PD, 19 with MSA, 10 with CBS,
15 with PSP, and 35 control patients without ophthalmologic,
inflammatory or degenerative neurological disease after obtaining
informed consent. They were consecutively recruited between
2009 and 2011 at the University Hospital Du ¨sseldorf, Germany.
All patients were clinically diagnosed and underwent long-term
follow-up examinations (mean follow up period 2562 months) and
the final diagnosis was established by the consensus of three
movement disorder specialists who were unaware of the OCT
results. PD, MSA, and PSP were diagnosed following the
established criteria [31,32,33,34]. Subjects with progressive
asymmetric parkinsonism, ideomotor apraxia and possible further
symptoms like dystonia, alien limb phenomenon, cortical sensory
loss, or myoclonia were classified as CBS [35]. All diagnoses were
established taking into consideration data of the longitudinal
neurologic follow-up examinations, possible response to dopami-
nergic treatment, diagnostic MRI, and in most cases scintigraphy
(FP-CIT-, IBZM- and MIBG-SPECT). Of the patients with MSA,
four had the cerebellar (MSA-C) and 16 the parkinsonian (MSA-P)
subtype. The UPDRS-III was determined after 12 h discontinu-
ation of anti-parkinsonian therapy [36], levodopa responsiveness
by a short-term levodopa test or by a clear qualitative levodopa
response during clinical follow-up. Corrected visual acuity was
assessed using Snellon charts and was above 6/10 for all eyes. All
patients received funduscopy and reported formal ophthalmologic
exams within three years before the examination. Subjects with a
history of retinopathy or glaucoma or high myopia were excluded
from the analysis and the 10% with the lowest values for macular
thickness and RNFL of each group underwent a second formal
ophthalmologic examination including slit lamp, visus and
tonometry after OCT to exclude a confounding ocular pathology.
Optical coherence tomography
The details of the principles of spectral-domain OCT have been
described elsewhere [37]. Using a Spectralis OCT device
(Heidelberg Engineering, Heidelberg, Germany) with image
alignment eye tracking-software (TruTrack, Heidelberg Engineer-
ing, Heidelberg, Germany), we obtained perifoveal volumetric
retinal scans consisting of 25 single horizontal axial scans (scanning
area: 666 mm, centered at the fovea, figure 1). To assess the
peripapillar RNFL, a circular scan with a diameter of approxi-
mately 3.4 mm was performed after manually positioning the
center on the middle of the optic disc (figure 1). Furthermore, we
performed high-resolution horizontal scans through the middle of
the fovea. All scans were performed with support of the eye-
tracking system, RNFL measurements and high resolution single
horizontal scans were averaged from 100 images and scans for
volumetric calculations from 10 (Automatic Real Time, ART).
Scans with poor quality (,20 DB) were excluded from the
analysis.
While the results of the RNFL- and paramacular volumetric
measurements were automatically segmented, the segmentation of
the different retinal layers in the single horizontal foveal scans was
performed manually by repositioning the measurement lines
(white dotted lines in figure 2) on the borders between the
different layers. The thickness of the different layers was measured
at the thickest point nasally and temporally of the macula using
Heidelberg Eye explorer software (vertical black lines in figure 2).
As in most subjects the outer nuclear layer (ONL) presents only
one central thickest point rather than nasal and temporal peaks as
in the other layers, we used the thickness at this point for analysis
(central vertical line in figure 2). In the few subjects with a nasal
and a temporal maximum of thickness, we used the higher value.
To assure test-retest reliability of the manual segmentation
method, 19 subjects were examined twice and the results for each
layer were correlated (Spearman).
Statistical Evaluation
Statistical analysis was performed using Microsoft Excel and
Prism 5.0 (Graphpad). Both eyes of each subject were included
into the analysis as statistically dependent duplicates. Analysis of
variance (ANOVA) was used with Dunnett’s multiple comparison
post-hoc test for comparison of all groups to controls and with
Tukey’s multiple comparison post-hoc test for comparison
between all pairs of columns. p-values below 0.05 were considered
as significant. In case of missing data the subject was excluded
from the respective analysis.
Sensitivity and specificity were calculated using the two-by-two
table method. The positive likelihood ratio (LR+) was calculated as
sensitivity/(1-specificity), the negative likelihood ratio (LR2) as (1-
sensitivity)/specificity. LR+ above 50 and LR2 below 0.05 were
considered excellent, LR+ from 10 to 50 and LR2 from 0.05 to
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between 0.1 and 0.3 fair.
Results
The patient groups and controls did not differ significantly in
age (exact age is depicted in supplemental table S1 and means in
table 1). The sex ratio did not differ significantly between controls
and/or patient groups except between MSA and CBS. We
observed no differences of any retinal layer between men and
women in our control group. Patients did not differ in disease
severity (UPDRS-Off). Disease duration was longer in PD, but did
not differ between the other groups (table 1, supplemental table
S1).
Routine Parameters RNFL and macular thickness
The peripapillar RNFL, paramacular thickness and volume,
and the thickness of the different retinal layers were measured as
illustrated in figure 1A, the results of all retinal parameters for the
Figure 1. Macular thickness is reduced in PSP. A The areas of
measurement are marked in an image of the fundus: The RNFL was
measured in a circular scan centered on the optic disc, macular
thickness and volume in scans around the macula, the manual
segmentation of the retinal layers was performed in a horizontal scan
through the center of the fovea. Scatter plots display the thickness of
the RNFL (B) and the total macular thickness (C). Each point represents
the mean of the two eyes of one patient. The mean of all patients is
indicated by a horizontal bar. Significant difference to the control group
is indicated by asterisks (p,0.05, ANOVA and Dunnett’s post-hoc test)
and significant difference between the patient groups by horizontal
bars (p,0.05, ANOVA and Tukey’s post-hoc test).
doi:10.1371/journal.pone.0034891.g001
Figure 2. Manual segmentation of the parafoveal retinal layers.
A and B The segmentation of the different retinal layers was performed
manually in single horizontal foveal scans, the images are displayed as
negatives to better differentiate the different layers. B shows a close-up
of A after manual segmentation, the retinal layers are divided by white
dotted lines. The thickness of the different layers was measured at
the vertical lines indicating the thickest point nasally and temporally of
the fovea, except for the ONL, which was measured centrally along the
vertical line. C–F Scatter plots of the mean thickness of the different
retinal layers. Each point represents the mean of the two eyes of one
patient. The mean of all patients is indicated by a horizontal bar.
Significant difference to the control group is indicated by asterisks
OCT in Parkinsonian Syndromes
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RNFL did not differ significantly between groups (figure 1B). The
mean total macular thickness and volume only of PSP patients
(30265.0 mm; 0.9560.02 mm
3) presented a significant reduction
compared to both controls (318.262.82 mm; 1.0260.01 mm
3) and
PD patients (317.562.6 mm; 1.01+20.01 mm
3) while the reduc-
tion observed in MSA (306.664.2 mm; 0.9860.01 mm
3) and CBS
(311.563.3 mm; 1.0060.01 mm
3) failed to reach significance
(figure 1C, volume not shown). The reduction of the macular
thickness in PSP affected both the peripheral and the central part
of the retina (reduction of 4.85% and 5.4% respectively, table 2),
and for the peripheral paramacular retinal thickness MSA patients
also differed significantly from controls (reduction of 4.1%, table 2).
Manual segmentation
Due to the high resolution of the last generation spectral-
domain OCT device used here, we were capable to identify the
different retinal layers in transfoveal scans. We manually
segmented the retinal layers in horizontal scans through the
middle of the fovea (figure 2A) and measured the thickness of the
different layers as indicated (figure 2B). The results are depicted in
table 2.
The retinal ganglion cell- and inner plexiform layer (RGC+IPL)
was reduced in PSP patients (87.362.7 mm) compared to controls
(98.561.7 mm) and PD patients (99.861.3 mm) (figure 2C).
Interestingly, the inner nuclear layer (INL) was thicker in patients
with PD (46.860.9 mm) compared to both controls (42.860.8 mm)
and patients with MSA (42.161.6 mm) and PSP (39.461.0 mm)
(figure 2D). We observed no significant differences in thickness of
the mean outer plexiform layer (OPL), however the nasal OPL
was significantly thicker in PSP compared to controls (figure 2E,
table 2). The thickness of the outer nuclear layer (ONL) was
reduced in PSP (93.962.2 mm) compared to controls
(105.961.7 mm), CBS (116.364.5 mm), and PD (107.863.6 mm)
(figure 2F).
To evaluate the possible implications of our findings for clinical
diagnostic procedures, we compared the intersections between the
atypical parkinsonian syndromes and PD. The most pronounced
differences were observed for ONL- and INL thickness between
PSP and PD. ONL thickness alone differentiated our PSP from
our PD patients with a sensitivity of 92% but with a sensitivity of
only 51% using a cutoff of 104 mm thickness as positive for PSP.
The ONL/OPL ratio and INL as indicators for PSP
As we observed reverse changes of ONL and OPL in our PSP
patients, we considered calculating the ratio between the two
layers to increase the discriminatory power. The ONL/OPL ratio
of PSP patients differed indeed significantly from controls and
patients with PD and CBS (figure 2G). Analyzing the INL/OPL
ratio revealed a particular distribution in CBS patients clustering
in two subgroups and a significant reduction in PSP compared to
PD and controls (figure 2H). However, the ONL/OPL ratio
showed the least overlap between these groups and thus served
best for differentiation. Using the ONL/OPL with a cutoff of 3.1,
we were able to differentiate between PSP and PD with a
sensitivity of 96% and a specificity of 59%. As this parameter was
not specific enough for our PSP patients, we used a combined test
taking into account also the INL. Including the INL into the
analysis with the constraint that only subjects with an INL below
46 mm were considered positive, we were able to raise the
specificity to 70% with a sensitivity of 96% to differentiate PSP
and PD in our cohort. The same test applied to the whole cohort
differentiated between PSP and all the other Parkinson syndromes
with a sensitivity of 96% and a specificity of 59%. As PSP is a rare
disorder, we calculated the positive and negative likelihood ratios
rather than the positive and negative predictive values to describe
the value of the test. We observed a good negative likelihood ratio
of 0.06 to discriminate between PSP and PD and 0.07 to
discriminate against all other parkinsonian syndromes. Due to the
rather low specificity of the test, the positive likelihood ratios for
PSP were only 3.4 for discrimination against PD and 2.4 for
discrimination against all Parkinson syndromes. No other
combination of tests or ratios was better able to differentiate
between PSP and PD or the other Parkinson syndromes.
Correlations
It is noteworthy that we observed no correlation between the
visual acuity of patients, the duration of disease, or the UPDRS-III
with the mean peripapillar RNFL, macular thickness, macular
volume, or any of the segmented retinal layers in any of the
Parkinson syndromes (Spearman, data not shown). The OFF
UPDRS-III of our PD patients did not differ from MSA, CBD, or
(p,0.05, ANOVA and Dunnett’s post-hoc test) and significant difference
between the patient groups by horizontal bars (p,0.05, ANOVA and
Tukey’s post-hoc test). G–H As some of the retinal layers showed
reverse changes in the different Parkinson syndromes. We calculated
their ratios to better discriminate the groups. G and H show scatter
plots of the ratio between the mean ONL/OPL thickness and the mean
INL/OPL thickness. Each point represents the mean of the two eyes of
one patient. The mean of all patients is indicated by a horizontal bar.
Significant difference to the control group is indicated by asterisks
(p,0.05, ANOVA and Dunnett’s post-hoc test) and significant difference
between the patient groups by horizontal bars (p,0.05, ANOVA and
Tukey’s post-hoc test).
doi:10.1371/journal.pone.0034891.g002
Table 1. Clinical parameters.
Age, y Duration, m Follow up, m H/Y scale UPDRSIII ON UPDRSIII OFF
PD 61.2+22.0 8.1+20.8 30.8+23.0 2.5+20.2 18.4+21.3 35.7+23.3
MSA 63.2+21.7 4.3+20.1 23.2+23.7 3.2+20.2 36.4+23.8 33.4+24.4
CBS 63.2+22.4 2.7+21.5 18.4+23.7 2.3+20.3 27.2+24.5 35.0+25.7
PSP 71.3+21.5 4.3+23.3 16.7+23.6 2.8+20.3 29.2+23.5 36.0+25.6
The means and the standard error of the means are indicated for the clinical parameters of the different Parkinson syndromes. Age is indicated in years (y), disease
duration and time of clinical follow up in months (m). The clinical scores Hoehn and Yahr (H/Y) scale and the score of the motor part of the unified parkinson’s disease
rating scale (UPDRS III) under best medication/deep brain stimulation (ON) and after .12 h without dopaminergic medication or deep brain stimulation (OFF) are
depicted.
doi:10.1371/journal.pone.0034891.t001
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and PSP indicating a similar severity of disease.
Discussion
The differential diagnosis of Parkinson syndromes is still a
clinical one and not always easy, especially at the onset of disease,
when clinical symptoms are mild and the responsiveness to L-
Dopa is ambiguous. Often, the final diagnosis can only be
established taking into account the further course of disease.
Several paraclinical tests including SPECT, MRI and transcranial
sonography have been developed to facilitate the diagnostic
process [38,39], the present study is the first to systematically
evaluate retinal changes in the differential diagnosis of Parkinson
syndromes.
Table 2. Complete dataset of OCT-parameters.
Control Control PD PD MSA MSA PSP PSP CBS CBS
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Mean RNFL 99.13 1.587 97.33 1.61 93.79 1.92 93.8 2.84 94.17 3.32
Temporal RNFL 73.89 2.017 73.08 2.12 72.37 3.45 65.07 2.35 69.3 3.35
Nasal RNFL 71.99 2.341 73.49 2.40 68.18 2.23 75.4 4.58 72.5 3.84
Superior RNFL 121.6 2.782 117.2 2.70 115.9 3.7 116.5 4.77 123.2 4.87
Inferior RNFL 126.7 3.063 127.2 2.53 118.4 4.16 117.1 3.95 118.6 5.65
Mean total MT 317.6 2.691 317.4 2.66 308.2 4.13 302.3* 5.02 311.5 3.30
Mean central MT 340.9 2.91 341.6 2.71 332.3 4.52 322.5* 5.95 334.9 3.90
Mean peripheral MT 294.3 2.604 293.5 2.53 283.9 3.67 280* 4.43 289.3 2.92
MT sup. peripheral 296 2.706 296.3 2.43 284.6 3.80 280.3* 4.61 294.5 3.54
MT inferior peripheral 285.1 2.75 284.8 2.39 277.4 3.27 271* 4.44 280.9 2.71
MT temp. peripheral 283.6 2.383 283.8 2.29 273.7 3.53 273.6 5.24 276 2.46
MT nasal peripheral 312.1 2.941 310.1 2.58 299,4* 4.06 291.5* 3.86 306.5 4.19
MT superior central 343.1 2.737 343.6 2.85 334.7 5.00 326.6* 7.24 337 4.22
MT inferior central 340.7 3.119 342.3 2.90 330.5 4.26 320.8* 6.32 334.8 3.42
MT temporal central 333.8 2.989 334 2.68 327.2 4.93 318,5* 7.83 326.5 3.16
MT nasal central 346.1 3.166 346.6 2.77 336.8 4.50 324* 4.21 341.2 5.21
Mean total MV 1.01 0.01 1.01 0.01 0.99 0.01 0.95* 0.02 1.00 0.01
Mean central MV 0.53 0.01 0.54 0.01 0.52 0.01 0.51 0.01 0.53 0.01
Mean peripheral MV 1.49 0.01 1.49 0.02 1.44 0.02 1.37* 0.02 1.46 0.02
MV sup. peripheral 1.52 0.01 1.51 0.01 1,45* 0.02 1.35* 0.05 1.49 0.03
MV inferior peripheral 1.44 0.02 1.47 0.02 1.41 0.02 1.28* 0.04 1.42 0.02
MV temp. peripheral 1.43 0.02 1.42 0.02 1.39 0.02 1.34 0.04 1.39 0.02
MV nasal peripheral 1.58 0.02 1.55 0.02 1.54 0.03 1.47* 0.04 1.56 0.03
MV superior central 0.53 0.01 0.53 0.01 0.53 0.01 0,51* 0.01 0.53 0.01
MV inferior central 0.53 0.01 0.54 0.01 0.52 0.01 0.53 0.04 0.57 0.04
MV temporal central 0.52 0.01 0.53 0.01 0.51 0.01 0,50* 0.01 0.51 0.01
MV nasal central 0.54 0.01 0.54 0.01 0.53 0.01 0.51* 0.01 0.54 0.01
Mean RGC+IPL 98.7 1.60 99.79 1.28 96.08 1.946 87.25* 2.74 94.42 1.75
Nasal RGC+IPL 103.1 1.58 102.5 1.50 97.23 1.49 89.96* 2.86 97.11 1.87
Temporal RGC+IPL 94.26 1.73 97.06 1.25 94.93 2.79 84.54* 2.72 91.72 2.65
Mean INL 42.79 0.69 46.8* 0.93 42.08 1.57 39.38 0.96 43.64 3.15
Nasal INL 44.63 0.89 48.19 1.04 44.1 1.483 40.43 1.40 46.28 3.62
Temporal INL 40.96 0.65 45.4* 1.01 40.07 1.84 38.32 0.87 41 3.03
Mean OPL 34.59 1.03 33.74 0.73 34.38 1.36 38.21 1.66 38.36 2.71
Nasal OPL 36.14 1.59 35.21 0.84 34.53 1.56 43.5* 3.25 41.17 4.60
Temporal OPL 33.03 0.93 32.26 0.76 34.23 1.61 32.93 0.75 35.56 1.83
Mean central ONL 105.1 1.71 105.8 2.46 104 2.29 93.92* 2.17 116.3* 4.49
The means and the standard error of the means are indicated for all acquired parameters in the different groups. Abbreviations are as follows: RNFL=peripapillar retinal
nerve fibre layer thickness in mm, MT=macular thickness in mm, MV=macular volume in mm3, RGC+IPL=retinal ganglion cell layer and inner plexiform layer measured
together in mm, INL=inner nuclear layer in mm, OPL=outer plexiform layer in mm, ONL=outer nuclear layer in mm. Means that significantly differed from the control
group are printed in bold and marked with an asterisk (p,0.05, ANOVA, Dunnett’s multiple comparison post-hoc test).
doi:10.1371/journal.pone.0034891.t002
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associated with distinct retinal alterations. The INL is thicker in
PD and thinner in PSP, while the ONL is thicker in CBS and
thinner in PSP. Calculating the ratio between the ONL and OPL
helped to identify patients with PSP. A combined test that also
considers changes in the INL can differentiate PSP from PD and
other Parkinson syndromes with a sensitivity of 96%. A good
negative likelihood ratio (,0.1) for this test indicates that a
negative result strongly argues against PSP. However, the
specificity to discriminate against the other Parkinson syndromes
was only 59% and against PD 70%. This translates to only fair
positive likelihood ratios (,4) which indicates that a positive test
result can be interpreted only as a hint favoring PSP and that the
other differential diagnoses are not ruled out.
The diagnostic relevance of changes in macular thickness is not
as easy to interpret. Our patients with MSA also had a non-
significant tendency to thinner paramacular layers and the
previously reported reduction of RNFL thickness in MSA failed
to reach significance in our study [30]. However, our MSA
patients presented a mean RNFL very close to the previous study
(93.8+/21.9 mm versus 91.9+/21.45 mm) [30] and an isolated
comparison of MSA patients and controls using a t-test showed
significance also for our cohort. Some previous publications on PD
[24,25,26] did report reductions of peripapillar RNFL or macular
thickness while others [28,29] did not, which was also the case in
the presented work. As the clinical differentiation of PD from the
atypical parkinsonian syndromes often necessitates taking in
account the course of disease and the previous studies do not
report neurological follow up, a possible explanation for the
discrepancies between studies could be that a percentage of
atypical patients were enrolled. We represent the study with the
largest number of PD patients to date and present data on patients
who were diagnosed at a specialized center for movement
disorders and clinically followed up over time, which largely
reduces the risk of diagnostic inaccuracy (supplemental table S1).
The functional consequences of the retinal changes observed
here are unknown and studies including functional tests like low
contrast letter recognition, multifocal ERGs and VEPs are already
underway to address this point.
Morphometric MRI studies have demonstrated brain atrophy
beyond the dopaminergic neurons of the substantia nigra not only
in atypical parkinsonian syndromes but also in PD [2,3,4,40,41].
In the retina, dopaminergic cells are mainly amacrine cells located
in the INL [42,43], and several functional studies have
demonstrated the importance of dopamine signaling for the visual
system (reviewed in [44]). However, the previously reported
reductions of RNFL and inner retina in PD [24,25,26] and
reduction of RNFL in MSA [30] are due to changes affecting the
RGCs or their axons. We observed changes of different retinal
layers involving different cell types. The ONL, which contains the
granule cells that link the rods and cones to the synaptic contacts
in the OPL, was thinner in PSP. We observed no significant
differences of the mean OPL where the synaptic contacts between
cells from the ONL and INL take place, however the nasal OPL
alone was thicker in PSP patients. Because in most patients the IPL
could not be precisely distinguished from the RGC layer, we
measured these layers together. The RGC+IPL contains the fibers
of Mueller and the synaptic contacts from the IPL as well as the
retinal ganglion cells, which make up the axons of the optic nerve.
This layer was reduced in PSP patients and we hypothesize that in
a larger collective the tendency to a thinner RGC+IPL observed in
MSA would also be significant.
Our finding that PSP and MSA patients present the most
profound retinal degeneration reflects what is seen in the brain of
these patients in comparative MRI studies, where morphometry
revealed the most pronounced atrophy in these two entities
compared to PD and controls [45,46,47]. The molecular
mechanisms underlying the retinal changes leave room for
speculation and should be investigated in a large histopathological
study. Possibly aggregation of protein tau might play a role in the
retinal degeneration observed in PSP. Tau deposition has been
detected in adult human retinae [48] and Alzheimer’s disease,
another common tauopathy, which also shows pronounced retinal
degeneration [49,50,51,52].
Our CBS cohort presented rather large variations in most
retinal parameters and the macular thickness and the ratio of
INL/OPL (figure 2H) even seemed to cluster in two subgroups. A
recent clinicopathological study re-evaluating cases clinically
diagnosed as corticobasal syndrome revealed a remarkably low
positive predictive value of the clinical diagnosis of CBS for
pathologically confirmation of corticobasal degeneration [53].
Possibly the variations observed in our cohort of patients with
clinical CBS resemble different pathologies.
The data presented here suggest that especially patients with
PSP may be interesting subjects for further functional studies of the
visual system as they may give insight into the functional
consequence of the morphological changes observed.
The fact that we observed no correlation between disease
duration and UPDRS-III scores in our cohort of patients with
manifest parkinsonian syndromes suggests that the retinal changes
occur already early in disease and may not show a pronounced
progression over time. Similar observations have been made for
transcranial sonography, where hyperechogenicity is already
observed early in PD (reviewed in [54]). This is of interest, as it
suggests that OCT might play a future role in the early differential
diagnosis of patients with Parkinson syndromes.
OCT is a fast, non-invasive, and cost-efficient method to assess
retinal morphology. The next generation of OCT devices is likely
to feature an automated segmentation of the different paramacular
retinal layers. This will largely facilitate similar studies in
parkinsonian syndromes and may open up the possibility to offer
OCT as a diagnostic tool for patients with movement disorders.
Our data suggest that the INL and ONL may be of special interest
in parkinsonian syndromes, as they were reversely affected in PD,
CBS, and PSP and thus may help to discriminate these diseases.
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